6β-Naltrexol-d4
Chemical compound
- None
- (1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)(13,14,15,15-2H4)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-triene-10,14,17-triol
- 1279034-32-0
- 46782432
- 58783513
- DTXSID501018245
- Interactive image
- O[C@@]1(C(C[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@]1([C@]2(CCN3CC6CC6)c45)[2H])([2H])[2H])[2H]
InChI
- InChI=1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1/i5D2,14D,18D
- Key:JLVNEHKORQFVQJ-NCRVCFHNSA-N
6β-Naltrexol-d4, also known as 6β-hydroxynaltrexone-d4, is a deuterium-labeled form of 6β-naltrexol used for NMR imaging. Unlike opioid inverse agonists such as naloxone and naltrexone (which are often dubbed "antagonists" for simplicity's sake), 6β-naltrexol and 6β-naltrexol-d4 are opioid neutral antagonists.[1]
References
- ^ Sirohi S, Dighe SV, Madia PA, Yoburn BC (August 2009). "The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity". The Journal of Pharmacology and Experimental Therapeutics. 330 (2): 513–9. doi:10.1124/jpet.109.152678. PMC 2713087. PMID 19435929.
- v
- t
- e
Opioid receptor modulators
(MOR)
(DOR)
(KOR)
(NOP)
Agonists |
|
---|---|
Antagonists |
|
- Enkephalinase inhibitors: Amastatin
- BL-2401
- Candoxatril
- D -Phenylalanine
- Dexecadotril (retorphan)
- Ecadotril (sinorphan)
- Kelatorphan
- Racecadotril (acetorphan)
- RB-101
- RB-120
- RB-3007
- Opiorphan
- Selank
- Semax
- Spinorphin
- Thiorphan
- Tynorphin
- Ubenimex (bestatin)
- Propeptides: β-Lipotropin (proendorphin)
- Prodynorphin
- Proenkephalin
- Pronociceptin
- Proopiomelanocortin (POMC)
- Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e